Preferences of patients with myeloproliferative neoplasms for accepting anxiety or depression treatment Journal Article

  

Authors:	McFarland, D. C.; Shen, M. J.; Polizzi, H.; Mascarenhas, J.; Kremyanskaya, M.; Holland, J.; Hoffman, R.
Article Title:	Preferences of patients with myeloproliferative neoplasms for accepting anxiety or depression treatment
Abstract:	Background Patients with chronic hematologic malignancies such as myeloproliferative neoplasms suffer from significant physical and psychological symptom burden. This study examined their willingness to accept an antidepressant and their preferences for which provider (mental health professional or hematologist/oncologist) prescribes an antidepressant for the management of anxiety and depression. Methods Anxiety and depression treatment preferences were measured with 3 questions assessing: (1) willingness to accept an antidepressant, (2) willingness to have their hematologist/oncologist prescribe the antidepressant, and (3) preference for treatment by a psychiatrist or mental health professional. Additionally, the Distress Thermometer and Problem List, Hospital Anxiety and Depression Scale, Risky Families Questionnaire, and demographic information were assessed to assess levels of distress, anxiety, and depression. Results Of the 117 participants, 69 (63.0%) were willing to accept an antidepressant in general and 61 (58.1%) were willing to accept an antidepressant from their hematologist/oncologist (p < 0.000). Although 41(39.0%) preferred to be treated by a mental health provider, this preference was not significantly associated with their respective preference for accepting an antidepressant (p = 0.057). Participants already taking antidepressants and those with elevated chronic stress levels were more willing to receive an antidepressant from their hematologist/oncologist (p = 0.035, p = 0.03, respectively). Treatment preferences did not vary based on myeloproliferative neoplasm type, length of time with myeloproliferative neoplasm, race/ethnicity, marital or working status, or by meeting distress/anxiety/depression criteria. A significant minority (n = 28, 26.7%) would not accept any treatment. Conclusion Most patients with myeloproliferative neoplasm accepted an antidepressant and readily accepted the prescription from their hematologist/oncologist. The hematologists/oncologist׳s psychopharmacologic knowledge and their willingness to prescribe antidepressants should be assessed. © 2017 The Academy of Psychosomatic Medicine.
Keywords:	depression; psycho-oncology; anxiety; antidepressants; cancer
Journal Title:	Psychosomatics
Volume:	58
Issue:	1
ISSN:	0033-3182
Publisher:	Elsevier Science, Inc.
Date Published:	2017-01-01
Start Page:	56
End Page:	63
Language:	English
DOI:	10.1016/j.psym.2016.08.006
PROVIDER:	scopus
PUBMED:	27745871
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-84991269154&doi=10.1016%2fj.psym.2016.08.006&partnerID=40&md5=25901732fbbee35056929def81d9123f
Notes:	Article -- Export Date: 3 January 2017 -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/103055